Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease for which no disease modifying treatment exists. Our groups, as part of the Spanish Cell Therapy Network (TerCel), have developed both preclinical and clinical evidence of the trophic effect of bone marrow mononuclear cells (BMNC) on the motor neurons that otherwise degenerate in ALS patients resulting in a progressive loss of muscular strength. We have demonstrated the safety of the intraspinal cord transplant of the BMNC in a phase I clinical trial, and replicated the protective trophic effect of the BMNCs seen in our animal models. We have also performed a phase I clinical trial on the intramuscular transplant of BMNC following our preclinical evidence of retrograde neurotrophic effects of the BMNC on the 2nd and even 1st motor neuron when transplanted intramuscularly. This trial showed the safety of the procedure and offered a potential biomarker of the disease evolution in the CMAP Scan D50 Index (D50). The transplanted Tibialis anterior (TA) muscles fared better than the contralateral placebo infused ones.We now propose a phase II randomized double blind clinical trial in which the experimetal patients will be tranplanted BMNC in the TA and hand's 1st dorsal inerosseous (1DI) of one side of the body and normal saline (NS) placebo in the other. According to the D50 results in our first intramuscular trial, the number needed to treat to achieve a 95% power with a <0.05 significance is 100 patients. Our main objective is to corroborate the safety results of our first clinical trial, to establish the protective effect of intramuscular BMNC by means of slowing down D50 deterioration both in the TA and in a new one: the 1DI. We will also observe the duration of the effect, as the intramuscular injections could possibly be repeated in the future.
terapia celular
esclerosis lateral amiotrófica
célula madre de médula ósea
índice D50 de CMAP
PAMC
potencial de acción muscular compuesto
trasplante intramuscular
Sepax
efecto trófico
Acción Estratégica en Salud (AES)
01/01/2019 - 31/12/2022
BLANQUER BLANQUER, MIGUEL
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
INSTITUTO MURCIANO DE INVESTIGACION BIOSANITARIA (IMIB)
Región de Murcia
Murcia
309,100 €